Randomized Phase III of PRRT Versus Interferon

Summary

The purpose of this study is to assess the benefit of 177Lu-DOTATATE versus interferon α-2b in patients with progressive, unresectable, non-pancreatic gastrointestinal neuroendocrine tumors resistant to therapy with somatostatin analogues, in terms of disease control.

Timeline

Start

2014-12

Primary completion

2016-10

Completion

2016-10

Drugs

Indications